½ÃÀ庸°í¼­
»óǰÄÚµå
1800746

À¯·´ÀÇ Â÷¼¼´ë ½ÉÇ÷°ü ÁßÀç½Ã¼ú ½ÃÀå : Á¦Ç° À¯Çüº°, ÀûÀÀÁõ À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - ºÐ¼®°ú ¿¹Ãø(2025-2035³â)

Europe Next-Generation Intervention Cardiology Market: Focus on Product Type, Indication Type, End User, and Country - Analysis and Forecast, 2025-2035

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: BIS Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 1-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

À¯·´ÀÇ Â÷¼¼´ë ½ÉÇ÷°ü ÁßÀç½Ã¼ú ½ÃÀå ±Ô¸ð´Â 2024³â 58¾ï 1,000¸¸ ´Þ·¯¿¡¼­ 2035³â 130¾ï 6,300¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ÀÎ 2025-2035³â 7.66%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Â÷¼¼´ë ½ÉÇ÷°ü ÁßÀç½Ã¼úÀº ÆÇ¸·Áõ, °ü»óµ¿¸ÆÁúȯ, ½ÉÀåÀÇ ±¸Á¶Àû °áÇÔ Ä¡·á¿¡ Á¤±³ÇÑ Àúħ½ÀÀûÀ̰í Á¤¹ÐÇÑ °¡À̵带 ÀÌ¿ëÇÑ ¹æ¹ýÀ» »ç¿ëÇÔÀ¸·Î½á À¯·´ ½ÉÀå Ä¡·á¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ß¿¡¼­´Â ±âÁ¸ÀÇ °³½É¼ú¿¡¼­ º¸´Ù ¾ÈÀüÇÏ°í °³ÀÎÈ­µÈ Ä«Å×Å͸¦ ÀÌ¿ëÇÑ ½Ã¼ú·ÎÀÇ º¯È­°¡ µÎµå·¯Áý´Ï´Ù. ·Îº¿°øÇÐ, AI¸¦ Ȱ¿ëÇÑ ¿µ»óó¸®, ÃÖ÷´Ü Àåºñ ±â¼úÀÌ À¯·´ ÀÇ»çµé¿¡ ÀÇÇØ ÅëÇÕµÇ¾î ½Ã¼úÀÇ ¾ÈÀü¼º, Á¤È®¼º, È¿À²¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÀÌ °³¹ßÀº ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí ȸº¹ ±â°£À» ´ÜÃàÇÏ´Â °Í ¿Ü¿¡µµ ÃÖ÷´Ü Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» ³ôÀ̰í, º´¿ø ÀÚ¿øÀ» ÃÖÀûÈ­Çϸç, °í·ÉÈ­ Àα¸¿¡ È¿À²ÀûÀÎ ½ÉÇ÷°ü ¼Ö·ç¼ÇÀ» Á¦°øÇÑ´Ù´Â À¯·´ÀÇ ÀÇ·á ¸ñÇ¥¸¦ Áö¿øÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
¿¹Ãø ±â°£ 2025-2035³â
2025³â Æò°¡ 61¾ï 2,670¸¸ ´Þ·¯
2035³â ¿¹Ãø 130¾ï 6,300¸¸ ´Þ·¯
CAGR 7.66%

½ÃÀå ¼Ò°³

À¯·´ÀÇ Â÷¼¼´ë ½ÉÇ÷°ü ÁßÀç½Ã¼ú ½ÃÀåÀº ÇコÄÉ¾î ½Ã½ºÅÛÀÌ º¹ÀâÇÑ ½ÉÇ÷°ü ÁúȯÀ» °ü¸®Çϱâ À§ÇØ ÃÖ¼Òħ½ÀÀûÀ̰í ȯÀÚ Áß½ÉÀÇ ¼Ö·ç¼ÇÀ» ¿ì¼±½ÃÇϸ鼭 ºü¸£°Ô º¯È­Çϰí ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â °ü»óµ¿¸ÆÁúȯ, ½ÉÀå ±¸Á¶ ÀÌ»ó, ÆÇ¸·Áõ µî ½ÉÇ÷°ü ÁúȯÀ¸·Î ÀÎÇÑ ÀÌȯÀ²°ú »ç¸Á·üÀÇ ÁÖ¿ä ¿øÀÎÀ¸·Î Ä«Å×Å͸¦ ÀÌ¿ëÇÑ Ã·´Ü ¼ö¼úÀÌ °³½É¼úÀ» ´ëüÇÏ´Â °æÇâÀÌ °­ÇØÁö°í ÀÖ½À´Ï´Ù. ÀÌ Áö¿ª¿¡¼­´Â ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí, Àç¿øÀϼö¸¦ ´ÜÃàÇϸç, ÀÇ·á ÀÚ¿øÀ» ÃÖ´ëÇÑ È°¿ëÇÏ´Â µ¥ ÁßÁ¡À» µÎ¾î ÀÌ·¯ÇÑ º¯È­¸¦ ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù.

Â÷¼¼´ë ½ÉÇ÷°ü ÁßÀç½Ã¼ú¿¡¼­´Â ·Îº¿°øÇÐ, AI¸¦ Ȱ¿ëÇÑ ¿µ»óó¸®, 3D ³×ºñ°ÔÀ̼Ç, ÷´Ü ±â±â ±â¼ú µîÀÌ Á¤È®¼º, ¾ÈÀü¼º, ½Ã¼úÀÇ È¿À²¼ºÀ» ³ôÀ̱â À§ÇØ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. À¯·´ Àü¿ªÀÇ ÀÇ·á½Ã¼³¿¡¼­ ¾à¹° ÄÚÆÃ Ç³¼±, »ýü Èí¼ö¼º ½ºÄ³Æúµå, °æÇÇÀû ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú(TAVR), °æÇÇÀû ½Â¸ðÆÇ¸· ġȯ¼ú(TMVR)°ú °°Àº Çõ½Å ±â¼úÀ» äÅÃÇÏ´Â ºñÀ²ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ã·´Ü Ä¡·áÀÇ º¸±ÞÀº ȯÀÚµéÀÌ º¸´Ù ½±°Ô Á¢±ÙÇÒ ¼ö ÀÖ´Â ÇÏÀ̺긮µåÇü Ä«Å×ÅÍ °Ë»ç½Ç°ú ¿Ü·¡Áø·á½Ã¼³ÀÇ ¼³¸³À¸·Î ´õ¿í ÃËÁøµÇ°í ÀÖ½À´Ï´Ù.

EUÀÇ MDR(ÀÇ·á±â±â ±ÔÁ¦)À» Æ÷ÇÔÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©´Â ´õ ³ôÀº ¾ÈÀü ±âÁذú ÀÓ»óÀû °ËÁõÀ» °­Á¦ÇÔÀ¸·Î½á Á¦Ç° ½ÂÀÎÀ» Çü¼ºÇϰí ÀÖ½À´Ï´Ù. ÇコÄɾî ÅõÀÚ Áõ°¡, °í·ÉÈ­, ÀÇ·á ±â¼ú ±â¾÷°ú Çмú ±â°üÀÇ °­·ÂÇÑ R&D Çù·Â°ú ÇÔ²² À¯·´Àº Â÷¼¼´ë ÁßÀç ½ÉÀåÇÐ ±â¼ú Çõ½Å°ú µµÀÔÀÇ Áß¿äÇÑ °ÅÁ¡À¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

¼¼ºÐÈ­ 1: Á¦Ç° À¯Çüº°

  • ·Îº¿
    • ·Îº¿ º¸Á¶ °æÇÇÀû °ü»óµ¿¸Æ ÁßÀç¼ú(R-PCI)
    • ·Îº¿ º¸Á¶ °ü»óµ¿¸Æ ¿ìȸ¼ú(RA-CABG)
    • ·Îº¿ º¸Á¶ ½Â¸ðÆÇ¸· ġȯ¼ú(RMVR)
    • ·Îº¿ º¸Á¶ ´ëµ¿¸Æ ÆÇ¸· ġȯ¼ú
  • ·Îº¿ ¿Ü
    • IVUS
    • OCT
    • ±âŸ °³ÀÔ
      • ½ºÅÙÆ®
      • Ä«Å×ÅÍ
      • °¡À̵å¿ÍÀ̾î
      • PTCA dz¼±
      • ±âŸ

¼¼ºÐÈ­ 2 : ÀûÀÀÁõ À¯Çüº°

  • ½ÉÀå ±¸Á¶ Áúȯ
  • °ü»óµ¿¸Æ Áúȯ
  • ½ÉÀå ÆÇ¸·Áõ
  • ¸»Ãʵ¿¸Æ Áúȯ
  • ¼±Ãµ¼º ½ÉÀåÁúȯ

ºÎ¹® 3: ÃÖÁ¾ »ç¿ëÀÚº°

  • º´¿ø ¹× Ŭ¸®´Ð
  • ½ÉÀå¼¾ÅÍ
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ

ºÎ¹® 4: Áö¿ªº°

  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ±âŸ

À¯·´ÀÇ Â÷¼¼´ë ½ÉÇ÷°ü ÁßÀç½Ã¼ú ½ÃÀå µ¿Çâ, ÃËÁø¿äÀÎ ¹× °úÁ¦

µ¿Çâ

¼ºÀå ÃËÁø¿äÀÎ

°úÁ¦

Á¦Ç°/Çõ½Å Àü·«: ÀÌ º¸°í¼­´Â À¯·´ÀÇ Â÷¼¼´ë ÁßÀçÀû ½ÉÀå Ä¡·á ºÐ¾ßÀÇ Ãֽбâ¼ú ¹ßÀü¿¡ ´ëÇÑ ±íÀº ÅëÂû·ÂÀ» Á¦°øÇÏ¿© ±â¾÷ÀÌ Çõ½ÅÀ» ÃËÁøÇÏ°í ½ÃÀå ¿ä±¸¿¡ ¸Â´Â ÃÖ÷´Ü Á¦Ç°À» °³¹ßÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

¼ºÀå/¸¶ÄÉÆÃ Àü·«: Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇϰí ÁÖ¿ä ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ¿© ±â¾÷ÀÌ Å¸°ÙÆÃµÈ ¸¶ÄÉÆÃ Àü·«À» ¼ö¸³ÇÏ°í ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ È¿°úÀûÀ¸·Î È®ÀåÇÒ ¼ö ÀÖ´Â Áö½ÄÀ» Á¦°øÇÕ´Ï´Ù.

°æÀï Àü·«: ÀÌ º¸°í¼­¿¡´Â À¯·´ÀÇ Â÷¼¼´ë ÁßÀçÀû ½ÉÀå Ä¡·á ½ÃÀå¿¡¼­ °æÀï»çÀÇ °­Á¡°ú ¾àÁ¡À» ÀÌÇØÇÏ°í ½ÃÀå¿¡¼­ °æÀï ¿ìÀ§¸¦ Á¡ÇÒ ¼ö ÀÖ´Â È¿°úÀûÀÎ Àü·«À» ¼ö¸³ÇÒ ¼ö ÀÖµµ·Ï öÀúÇÑ °æÀï ȯ°æ ºÐ¼®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

±ÔÁ¦ ¹× ÄÄÇöóÀ̾𽺠Àü·« À¯·´ÀÇ Â÷¼¼´ë ½ÉÇ÷°ü ÁßÀç½Ã¼ú¿¡ ƯȭµÈ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, ½ÂÀÎ ¹× ¾÷°è °¡À̵å¶óÀο¡ ´ëÇÑ ÃֽŠÁ¤º¸¸¦ Á¦°øÇÏ¿© ±â¾÷ÀÌ ÄÄÇöóÀ̾𽺸¦ ÁؼöÇÏ°í »õ·Î¿î Â÷¼¼´ë ½ÉÇ÷°ü ÁßÀç½Ã¼ú ½ÃÀå ÁøÀÔÀ» °¡¼ÓÈ­ÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù.

ÅõÀÚ ¹× »ç¾÷ È®Àå Àü·«: ½ÃÀå µ¿Çâ, ÀÚ±Ý Á¶´Þ ÆÐÅÏ, Á¦ÈÞ ±âȸ µîÀ» ºÐ¼®ÇÏ¿© ±â¾÷ÀÌ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, »ç¾÷ ¼ºÀåÀ» À§ÇÑ ÀáÀçÀûÀÎ M&A ±âȸ¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷ ¹× °æÀï»ç ¿ä¾à

±â¾÷ ÇÁ·ÎÆÄÀÏÀº 1Â÷ Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ Àǰ߰ú ±â¾÷ Ä¿¹ö¸®Áö, Á¦Ç° Æ÷Æ®Æú¸®¿À, ½ÃÀå ħÅõµµ ºÐ¼®À» ¹ÙÅÁÀ¸·Î ¼±Á¤µË´Ï´Ù.

ÀÌ ½ÃÀå¿¡ ÁøÃâÇÑ À¯¸í ±â¾÷µéÀº ´ÙÀ½°ú °°½À´Ï´Ù.

  • B. Braun SE
  • Koninklijke Philips N.V.
  • Siemens Healthineers AG

¸ñÂ÷

ÁÖ¿ä ¿ä¾à

Á¦1Àå Â÷¼¼´ë ½ÉÇ÷°ü ÁßÀç½Ã¼ú ½ÃÀå : ¾÷°è Àü¸Á

  • °æÀï ±¸µµ
  • Â÷¼¼´ë ½ÉÇ÷°ü ÁßÀç½Ã¼ú ½ÃÀå : Áø´Ü°ú °ü¸®
  • °ü»óµ¿¸Æ ÁßÀç¼úÀÇ Áøº¸
  • °ü»óµ¿¸Æ ÁßÀç¼úÀÇ ÇâÈÄ ¹æÇ⼺°ú ½Å±â¼ú
  • Â÷¼¼´ë ½ÉÇ÷°ü ÁßÀç½Ã¼ú ½ÃÀå ÆÄÀÌÇÁ¶óÀÎ Á¦Ç°
  • ±ÔÁ¦ »óȲ
    • À¯·´

Á¦2Àå ½ÃÀå ¿ªÇÐ

  • µ¿Çâ
  • ½ÃÀå ¿ªÇÐ

Á¦3Àå Â÷¼¼´ë ½ÉÇ÷°ü ÁßÀç½Ã¼ú ½ÃÀå(Áö¿ªº°), ±Ý¾×, 2024³â-2035³â

  • Áö¿ª ¿ä¾à
  • À¯·´
    • Áö¿ª °³¿ä
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ±âŸ

Á¦4Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

  • ±â¾÷ °³¿ä
    • Siemens Healthineers AG
    • Koninklijke Philips N.V.
    • B. Braun SE

Á¦5Àå Á¶»ç ¹æ¹ý

LSH 25.09.05

This report can be delivered in 2 working days.

Introduction to Europe Next-Generation Intervention Cardiology Market

The Europe next-generation intervention cardiology market is projected to reach $13,063.0 million by 2035 from $5,800.1 million in 2024, growing at a CAGR of 7.66% during the forecast period 2025-2035. Next-generation interventional cardiology is revolutionizing cardiac treatment in Europe by using sophisticated, minimally invasive, precision-guided methods to treat valvular diseases, coronary artery disease, and structural heart defects. There has been a noticeable change in the area from traditional open heart surgery to safer, more individualized catheter-based procedures. Robotics, AI-enhanced imaging, and cutting-edge device technologies are being integrated by European doctors to increase procedure safety, accuracy, and efficiency. In addition to improving patient outcomes and shortening recovery periods, this development supports Europe's healthcare aims of increasing access to cutting-edge therapies, optimizing hospital resources, and providing efficient cardiovascular solutions to an aging population.

KEY MARKET STATISTICS
Forecast Period2025 - 2035
2025 Evaluation$6,126.7 Million
2035 Forecast$13,063.0 Million
CAGR7.66%

Market Introduction

The Europe Next-Generation Interventional Cardiology Market is undergoing a rapid transformation as healthcare systems prioritize minimally invasive, patient-centric solutions for managing complex cardiovascular diseases. Advanced catheter-based operations are increasingly replacing open heart surgeries as the primary source of morbidity and mortality in Europe due to cardiovascular illnesses such coronary artery disease, structural heart abnormalities, and valvular disorders. The region's focus on enhancing patient outcomes, cutting hospital stays, and making the most of healthcare resources is what is causing this change.

Robotics, AI-powered imaging, 3D navigation, and advanced device technologies are all used in next-generation interventional cardiology to improve accuracy, safety, and procedural efficiency. Healthcare facilities throughout Europe are adopting innovations including drug-coated balloons, bioresorbable scaffolds, transcatheter aortic valve replacement (TAVR), and transcatheter mitral valve repair (TMVR) at an increasing rate. The spread of these cutting-edge therapies is further supported by the establishment of hybrid cath laboratories and ambulatory facilities, which provide greater accessibility for patients.

Regulatory frameworks, including the EU MDR (Medical Device Regulation), are shaping product approvals by enforcing higher safety standards and clinical validation. Coupled with rising healthcare investments, an aging population, and strong R&D collaborations between medtech companies and academic institutions, Europe is positioned as a key hub for next-generation interventional cardiology innovation and adoption.

Market Segmentation

Segmentation 1: By Product Type

  • Robotics
    • Robotic-Assisted Percutaneous Coronary Intervention (R-PCI)
    • Robotic-Assisted Coronary Artery Bypass Grafting (RA-CABG)
    • Robotic Assisted Mitral Valve-Replacement (RMVR)
    • Robotic Assisted Aortic Valve Replacement
  • Non-Robotics
    • IVUS
    • OCT
    • Other Interventions
      • Stents
      • Catheters
      • Guidewires
      • PTCA Balloons
      • Others

Segmentation 2: By Indication Type

  • Structural Heart Disease
  • Coronary Heart Diseases
  • Valvular Heart Diseases
  • Peripheral Artery Diseases
  • Congenital Heart Diseases

Segmentation 3: By End User

  • Hospitals and Clinics
  • Cardiac Centers
  • Ambulatory Surgical Centers

Segmentation 4: By Region

  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest-of-Europe

Europe Next-Generation Intervention Cardiology Market Trends, Drivers and Challenges

Trends

  • Growing adoption of minimally invasive procedures using next-gen stents, balloons, and catheters.
  • Expansion of transcatheter therapies (e.g., TAVR, TMVR) as alternatives to open-heart surgery.
  • Integration of robotics and image-guided systems to enhance precision and reduce complications.
  • Rising use of drug-coated balloons, bioresorbable scaffolds, and novel stent materials.
  • Increasing application of AI, machine learning, and 3D imaging in procedure planning and real-time guidance.
  • Strong growth in ambulatory cardiac care centers and hybrid operating rooms across Europe.

Drivers

  • High prevalence of cardiovascular diseases due to aging populations and lifestyle factors.
  • Growing demand for less invasive, faster-recovery treatments compared to conventional surgery.
  • Technological innovation supported by European medical device companies and research institutions.
  • Supportive EU healthcare policies and reimbursement frameworks for advanced cardiac interventions.
  • Rising investments in digital health, telecardiology, and remote patient monitoring.
  • Increasing awareness and early diagnosis of coronary and structural heart diseases.

Challenges

  • High cost of next-gen interventional devices and robotic systems limiting access in some regions.
  • Variability in reimbursement policies across EU member states.
  • Steep learning curve and training requirements for interventional cardiologists adopting new technologies.
  • Regulatory hurdles for CE marking and EU MDR compliance delaying product launches.
  • Competition from conventional procedures and alternative therapies.
  • Limited availability of infrastructure such as hybrid cath labs in smaller hospitals.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in Europe next-generation intervention cardiology, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses in Europe next-generation intervention cardiology and allowing them to strategize effectively to gain a competitive edge in the market.

Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines specific to Europe next-generation intervention cardiology, ensuring organizations stay compliant and accelerate market entry for new next-generation intervention cardiology

Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts, as well as analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • B. Braun SE
  • Koninklijke Philips N.V.
  • Siemens Healthineers AG

Table of Contents

Executive Summary

Scope and Definition

1 Next-Generation Intervention Cardiology Market: Industry Outlook

  • 1.1 Competitive Landscape
    • 1.1.1 Business Strategies
      • 1.1.1.1 Product Developments in Next-Generation Intervention Cardiology Market
  • 1.2 Next-Generation Intervention Cardiology Market: Diagnosis and Management
  • 1.3 Advancements in Coronary Intervention
  • 1.4 Future Direction and Emerging Technologies in Coronary Interventions
  • 1.5 Pipeline Products in the Next-Generation Intervention Cardiology Market
  • 1.6 Regulatory Landscape
    • 1.6.1 Europe

2 Market Dynamics

  • 2.1 Trends
    • 2.1.1 Trends in the Next-Generation Intervention Cardiology Market
      • 2.1.1.1 Shift towards Minimally Invasive and Percutaneous Procedures Transforming Treatment Paradigms
      • 2.1.1.2 Integration of AI-Predictive Intelligence in Intervention Cardiology
        • 2.1.1.2.1 AI in Imaging, Lesion Assessment, and Diagnostics
  • 2.2 Market Dynamics
    • 2.2.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment
    • 2.2.2 Market Drivers
      • 2.2.2.1 Rising Elderly Population, Driving Demand for Advanced Cardiac Interventions
        • 2.2.2.1.1 Cardiovascular Disease Burden in the Elderly
      • 2.2.2.2 Emergence of Robotic-Assisted Interventions- Enhancing Procedural Accuracy and Operator Control
    • 2.2.3 Market Restraints
      • 2.2.3.1 High Procedural Cost and Infrastructure Burden Limiting Broad Adoption
      • 2.2.3.2 Regulatory Complexity and Prolonged Approval Timelines Hindering Innovation
        • 2.2.3.2.1 Lengthy Approval Pathways for High-Risk Devices
        • 2.2.3.2.2 Lack of Harmonization across Geographies
        • 2.2.3.2.3 Regulatory Gaps for AI and Software-Driven Devices
    • 2.2.4 Market Opportunities
      • 2.2.4.1 Stent and Balloon Innovation Unlocking Next-Generation Use Cases
        • 2.2.4.1.1 Advancements in Drug-Coated Balloon Technologies
      • 2.2.4.2 Remote and Robotic-Enabled Expansion into Emerging Markets
        • 2.2.4.2.1 Bridging Access Gaps through Remote Robotics
    • 2.2.5 Market Challenges
      • 2.2.5.1 Data Standardization and Clinical Validation Gaps in AI-Driven Cardiology
      • 2.2.5.2 Safety and Clinical Validation Barriers for Next-Generation Vascular Implants

3 Next-Generation Intervention Cardiology Market (Region), Value ($million), 2024-2035

  • 3.1 Regional Summary
  • 3.2 Europe
    • 3.2.1 Regional Overview
    • 3.2.2 Driving Factors for Market Growth
    • 3.2.3 Factors Challenging the Market
    • 3.2.4 U.K.
    • 3.2.5 France
    • 3.2.6 Germany
    • 3.2.7 Italy
    • 3.2.8 Spain
    • 3.2.9 Rest-of-Europe

4 Competitive Landscape and Company Profiles

  • 4.1 Company Profiles
    • 4.1.1 Siemens Healthineers AG
      • 4.1.1.1 Overview
      • 4.1.1.2 Top Products/Product Portfolio
      • 4.1.1.3 Top Competitors
      • 4.1.1.4 Target Customers
      • 4.1.1.5 Strategic Positioning and Market Impact
      • 4.1.1.6 Analyst View
      • 4.1.1.7 Pipeline and Research Initiatives
    • 4.1.2 Koninklijke Philips N.V.
      • 4.1.2.1 Overview
      • 4.1.2.2 Top Products/Product Portfolio
      • 4.1.2.3 Top Competitors
      • 4.1.2.4 Target Customers
      • 4.1.2.5 Strategic Positioning and Market Impact
      • 4.1.2.6 Analyst View
      • 4.1.2.7 Pipeline and Research Initiatives
    • 4.1.3 B. Braun SE
      • 4.1.3.1 Overview
      • 4.1.3.2 Top Products/Product Portfolio
      • 4.1.3.3 Top Competitors
      • 4.1.3.4 Target Customers
      • 4.1.3.5 Strategic Positioning and Market Impact
      • 4.1.3.6 Analyst View
      • 4.1.3.7 Pipeline and Research Initiatives

5 Research Methodology

  • 5.1 Data Sources
    • 5.1.1 Primary Data Sources
    • 5.1.2 Secondary Data Sources
    • 5.1.3 Inclusion and Exclusion
    • 5.1.4 Data Triangulation
  • 5.2 Market Estimation and Forecast
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦